Literature DB >> 26499762

Head-To-Head Assessment of Diagnostic Performance of Testosterone Immunoassays in Patients With Polycystic Ovary Syndrome.

Andreas N Schüring1, Stefan Nolte2, Manfred Fobker2, Frank Kannenberg2, Jerzy-Roch Nofer3.   

Abstract

BACKGROUND: Determination of plasma testosterone is critical for the proper diagnosis of polycystic ovary syndrome (PCOS), but the interpretation of biochemical tests is hampered by inadequate specificity and precision of available immunoassays. We here compared the diagnostic performance of three testosterone immunoassays (Advia Centaur, Immulite 2000 XPi, Cobas e411) in PCOS patients using receiver operator characteristics curve analysis. METHODS AND
RESULTS: Plasma levels of testosterone, androstendione, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, estradiol, progesterone, steroid hormone binding globulin, luteinizing hormone, and follicular stimulating hormone were determined in 188 patients with PCOS and 202 controls. Free testosterone (fT) levels and free androgen index (FAI) were calculated. Testosterone levels measured on Advia Centaur, Immulite 2000 XPi, and Cobas e411 showed clear linear relationship to each other. Testosterone measured with Advia Centaur showed discriminatory performance superior to Immulite 2000 XPi and Cobas e411. Calculation of fT or FAI improved the performance of Advia Centaur and Immulite 2000 XPi, which nevertheless performed better than Cobas e411. The performance of other parameters was inferior to that of testosterone, fT, and FAI.
CONCLUSION: Present study documents striking differences between testosterone immunoassays with respect to their capacity to identify PCOS patients and favors the use of calculated parameters reflecting active testosterone in plasma.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  immunoassay; polycystic ovary syndrome; receiver operating characteristic curves; testosterone

Mesh:

Substances:

Year:  2015        PMID: 26499762      PMCID: PMC6807039          DOI: 10.1002/jcla.21882

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  14 in total

1.  Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.

Authors:  Ricardo Azziz; Enrico Carmina; Didier Dewailly; Evanthia Diamanti-Kandarakis; Hector F Escobar-Morreale; Walter Futterweit; Onno E Janssen; Richard S Legro; Robert J Norman; Ann E Taylor; Selma F Witchel
Journal:  J Clin Endocrinol Metab       Date:  2006-08-29       Impact factor: 5.958

2.  Role of the CAG repeat polymorphism of the androgen receptor gene in polycystic ovary syndrome (PCOS).

Authors:  A N Schüring; A Welp; J Gromoll; M Zitzmann; B Sonntag; E Nieschlag; R R Greb; L Kiesel
Journal:  Exp Clin Endocrinol Diabetes       Date:  2011-11-08       Impact factor: 2.949

3.  Selected performance characteristics of the Roche Elecsys testosterone II assay on the Modular analytics E 170 analyzer.

Authors:  William E Owen; Mindy L Rawlins; William L Roberts
Journal:  Clin Chim Acta       Date:  2010-04-10       Impact factor: 3.786

4.  Receiver operating characteristic analysis of the performance of basal serum hormone profiles for the diagnosis of polycystic ovary syndrome in epidemiological studies.

Authors:  H F Escobar-Morreale; M Asunción; R M Calvo; J Sancho; J L San Millán
Journal:  Eur J Endocrinol       Date:  2001-11       Impact factor: 6.664

5.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1983-09       Impact factor: 11.105

6.  Assessment of diagnostic competence of plasmatic androgens on polycystic ovary syndrome based on receiver operator characteristic curves.

Authors:  Claudio Villarroel; León Trejo; Alex Muñoz; Paulina Kohen; Ariel Fuentes; Luigi Devoto
Journal:  Gynecol Endocrinol       Date:  2010-08       Impact factor: 2.260

7.  Diagnostic value of calculated testosterone indices in the assessment of polycystic ovary syndrome.

Authors:  Susanne Hahn; Werner Kuehnel; Susanne Tan; Karen Kramer; Markus Schmidt; Susanne Roesler; Rainer Kimmig; Klaus Mann; Onno E Janssen
Journal:  Clin Chem Lab Med       Date:  2007       Impact factor: 3.694

Review 8.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

Authors: 
Journal:  Hum Reprod       Date:  2004-01       Impact factor: 6.918

9.  The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone.

Authors:  M P Lauritsen; J G Bentzen; A Pinborg; A Loft; J L Forman; L L Thuesen; A Cohen; D M Hougaard; A Nyboe Andersen
Journal:  Hum Reprod       Date:  2014-01-16       Impact factor: 6.918

10.  Defining hyperandrogenism in polycystic ovary syndrome: measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots.

Authors:  Julian H Barth; Helen P Field; Ephia Yasmin; Adam H Balen
Journal:  Eur J Endocrinol       Date:  2009-12-14       Impact factor: 6.664

View more
  1 in total

1.  Cut-off levels for hyperandrogenemia among Samoan women: An improved methodology for deriving normative data in an obese population.

Authors:  Hasina Maredia; Geralyn M Lambert-Messerlian; Glenn E Palomaki; Satupaitea Viali; Nicola L Hawley; Stephen T McGarvey
Journal:  Clin Biochem       Date:  2016-02-18       Impact factor: 3.281

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.